Barclays
SRRA

Barclays’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Barclays’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-60,000
Closed -$1.92M – 5479
2022
Q1 		$1.92M Buy
+60,000
New +$1.72M ﹤0.01% 1889

Other funds holding SRRA

HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Barclays's SRRA Position: Q3 2022 in Review

Barclays sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 9,304 shares — an estimated $512K sold.

Barclays first reported a position in SRRA in Q4 2015 and held it in 11 quarters. The position peaked at $721K in Q1 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

  • Barclays reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 9,304 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $512K.
  • Barclays first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2015 and held it in 11 quarters.
  • Barclays's Sierra Oncology, Inc. Common Stock position peaked at $721K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.